Latest News and Press Releases
Want to stay updated on the latest news?
-
RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025RAP-219 Phase 2a trial in patients with bipolar mania...
-
Rapport Therapeutics to Participate in Upcoming Investor Conferences
-
Rapport will present two encore posters at the American Academy of Neurology Annual Mtg - data on RAP-219, which is in current Ph2a trial in focal epilepsy
-
Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
Rapport appoints Dr. Jeffrey Sevigny as CMO, a physician-scientist with more than 15 years of translational and clinical drug development
-
Rapport Therapeutics will participate in fireside chats at the upcoming TD Cowen 45th Annual Health Care Conference and Stifel 2025 Virtual CNS Forum.
-
Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.
-
Rapport announced new data from its Phase 1 PET and MAD-2 trials for RAP-219 being studied as a novel precision medicine for patients with CNS disorders.
-
Rapport presents new data on the linear relationship between a seizure biomarker used in the company's RAP-219 POC trial and clinical seizures.
-
BOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule...